1. Home
  2. RM vs FHTX Comparison

RM vs FHTX Comparison

Compare RM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regional Management Corp.

RM

Regional Management Corp.

N/A

Current Price

$32.32

Market Cap

390.4M

Sector

Finance

ML Signal

N/A

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

N/A

Current Price

$5.50

Market Cap

332.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RM
FHTX
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.4M
332.2M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
RM
FHTX
Price
$32.32
$5.50
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$30.00
$11.71
AVG Volume (30 Days)
51.5K
103.0K
Earning Date
05-06-2026
04-14-2026
Dividend Yield
3.72%
N/A
EPS Growth
7.49
32.48
EPS
4.45
N/A
Revenue
$645,598,000.00
$22,602,000.00
Revenue This Year
$12.83
$40.87
Revenue Next Year
$7.93
$11.27
P/E Ratio
$7.23
N/A
Revenue Growth
9.70
N/A
52 Week Low
$25.41
$2.94
52 Week High
$46.00
$6.95

Technical Indicators

Market Signals
Indicator
RM
FHTX
Relative Strength Index (RSI) 40.12 46.73
Support Level $30.85 $4.44
Resistance Level $35.30 $5.85
Average True Range (ATR) 1.46 0.33
MACD 0.04 -0.01
Stochastic Oscillator 24.31 39.43

Price Performance

Historical Comparison
RM
FHTX

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: